GSK3 Jul 2021 00:34
From the times
Separately, the group announced that it had struck a deal worth as much $2.2 billion to partner with Alector to develop two of the California-based group’s antibody treatments to tackle neurodegenerative disorders, including Parkinson’s and Alzheimer’s.
Under the terms of the deal, the British group will pay Alector $700 million up front, with a further $1.5 billion due to the US company if certain clinical development and regulatory milestones are met